title: Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.
abstract: This retrospective analysis was performed to determine the clinical and bacteriologic efficacy of the ketolide antibacterial telithromycin in patients with community-acquired pneumonia (CAP) with pneumococcal bacteremia. Patients 13 years old with radiologically confirmed CAP and a positive blood culture for Streptococcus pneumoniae at screening were analyzed from eight multicenter Phase III/IV clinical trials. In four open-label, non-comparative studies, patients received telithromycin 800 mg once daily for 7-10 days. In four randomized, controlled, double-blind, comparative studies, patients received telithromycin 800 mg once daily for 5-10 days or a comparator antimicrobial (amoxicillin 1000 mg three times daily, clarithromycin 500 mg twice daily, or trovafloxacin 200 mg once daily) for 7-10 days. In total, 118 patients (telithromycin, 94/1061 [8.9%]; comparator, 24/244 [9.8%]) had documented pneumococcal bacteremia. Those who were treated with telithromycin achieved a clinical cure rate of 90.2% (74/82, per-protocol population); S. pneumoniae was eradicated in 77/82 (93.9%) bacteremic patients who received telithromycin and 15/19 (78.9%) comparator-treated patients. Clinical cure was also observed among telithromycin-treated bacteremic patients who were infected with penicillin- or erythromycin-resistant strains of S. pneumoniae (5/7 and 8/10, respectively). In conclusion, telithromycin achieves high clinical and bacteriologic cure rates in CAP patients with pneumococcal bacteremia.
authors.affiliation: claude_carbon32@hotmail.com
authors.forename: C
authors.initials: C
authors.lastname: Carbon
authors.forename: D
authors.initials: D
authors.lastname: van Rensburg
authors.forename: L
authors.initials: L
authors.lastname: Hagberg
authors.forename: C
authors.initials: C
authors.lastname: Fogarty
authors.forename: G
authors.initials: G
authors.lastname: Tellier
authors.forename: M
authors.initials: M
authors.lastname: Rangaraju
authors.forename: R
authors.initials: R
authors.lastname: Nusrat
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017327:Clinical Trials, Phase IV as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D006801:Humans; D048628:Ketolides / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; C106791:telithromycin